What is Calciphylaxis?
Calciphylaxis is a rare and life-threatening complication of chronic kidney disease-mineral and bone disorder (CKD-MBD) characterized by calcification and thrombosis of small to medium-sized blood vessels in the dermis and subcutaneous adipose tissue, leading to painful skin necrosis with exceptionally high mortality rates. 1
Clinical Presentation and Pathophysiology
Calciphylaxis manifests as:
- Exquisitely painful subcutaneous nodules that progress to nonhealing ulcerations and skin necrosis 2, 3
- Reticular and confluent patterns of subcutaneous calcifications visible on imaging 2
- Ischemic tissue damage from microvascular occlusion 4
The condition results from calcium deposition in dermal and adipose microvasculature, causing endothelial damage, microthrombi formation, and subsequent tissue ischemia 4, 5. While most commonly seen in end-stage renal disease patients on dialysis, it can also occur in acute kidney injury 5.
Key Risk Factors
The most critical modifiable risk factor is vitamin K antagonist use - patients on dialysis taking warfarin have an up to 11-fold increased risk of developing calciphylaxis 1. This represents the single most important preventable trigger.
Other significant risk factors include:
- Calcification inducers: High-dose active vitamin D derivatives 1
- Lack of calcification inhibitors: Vitamin K deficiency, chronic inflammation 1
- Excess calcium and phosphate exposure 1
- Secondary hyperparathyroidism 6
- Type 2 diabetes mellitus 2
Diagnostic Challenges
Skin biopsy is unreliable for diagnosing calciphylaxis and should be avoided when possible 1. The evidence is clear on this critical point:
- 30% of biopsies have inadequate sampling 1
- Sensitivity ranges only 20-80% 1
- No established or validated histologic diagnostic criteria exist 1
- Biopsy traumatizes vulnerable tissue and may trigger additional nonhealing ulcers 1
Instead, diagnosis should be primarily clinical, based on:
- Recognition of characteristic painful skin lesions in at-risk patients 5, 3
- Radiographic findings showing subcutaneous calcifications on plain films or CT 2
- Clinical context (CKD, dialysis, risk factor exposure) 3
Management Principles
Immediately limit exposure to excess calcium and phosphate, even though serum levels are not predictive of outcomes 1. This paradox is important - while you cannot use calcium and phosphate levels to guide therapy or predict prognosis, reducing exposure remains essential.
Discontinue vitamin K antagonists immediately given the 11-fold increased risk 1.
Avoid calcification inducers such as high-dose active vitamin D derivatives 1.
Emerging Therapies
The most promising treatment based on recent evidence is SNF472 (hexaphosphate phytate). In the CALCIPHYX trial, SNF472 demonstrated:
- Improvements in wound healing (measured by modified Bates Jensen Wound Assessment Tool) 1
- Reduced pain scores 1
- Fewer deaths and hospitalizations compared to placebo 1
Sodium thiosulfate is frequently used for its vasodilatory, antioxidant, and calcium-chelating properties 6, though optimal duration remains undefined and requires individualized assessment based on clinical response 6.
Prognosis
Calciphylaxis carries exceptionally high morbidity and mortality rates 4, 5, 3. The condition causes severe, intractable pain and slow-healing wounds that significantly impair quality of life 3. Early recognition and prompt multidisciplinary intervention are critical to improving survival 7.